Antibe - A low risk buyAntibe is either doing 'B' or has probably bottomed out.
Trend lines and crossovers also support an up move.
Very likely to hit the 1st target. Could hit the second and continue the up move if the +ve divergence stays.
−0.2564USD
−14.143MUSD
47.682M
About Antibe Therapeutics, Inc.
Sector
CEO
Daniel Legault
Headquarters
Toronto
Website
Employees (FY)
11
Founded
2009
ISIN
CA0370255097
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment is involved in the development and sale of regenerative medicines serving the dental and orthopedic marketplaces. The company was founded by Andre Buret, John Wallace, and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada.
inverse head and shouldersOn the daily we have the rsi above the 50 level pointing up up and a macd kiss on the positive side. Looking at the price action we can see the price action above the 8, 21, and 55 ema , but will under the 200 ema, as well as a neckline for a possible inverse head and shoulders breakout. They have
$ATBPF Antibe Therapeutics Inc, bull run to continue?Trade opportunity to the top of a well defined channel, with a possible 13% gain.
Indicators quite bullish as MACD reverses of the zero line, histogram ticking higher and green.
RSI in strong move.
Company profile
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the developmen
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
